Treatment of Advanced Hodgkin’s Disease with [1,3 Bis (2-Chloroethyl)-1-Nitrosourea] BCNU
- 26 August 1971
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 285 (9), 475-479
- https://doi.org/10.1056/nejm197108262850902
Abstract
The nitrosoureas are a new class of antitumor agents that have demonstrated activity against several human tumors. BCNU, a member of this class, was used to treat 45 patients with far advanced, previously treated Hodgkin's disease. Twenty-one patients (47 per cent) achieved an appreciable remission. Nineteen patients had a partial remission for 16.5 weeks. Two patients had complete remissions for 72 and 208 weeks respectively. Leukopenia occurred in 24 patients, and thrombocytopenia in 32. BCNU has activity against Hodgkin's disease even when the disease is resistant to standard chemotherapeutic agents, and it appears not to be cross-resistant with the alkylating agents.Keywords
This publication has 4 references indexed in Scilit:
- Combination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1970
- BCNU (1,3), BIS(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasiaCancer, 1968
- The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animalsClinical Pharmacology & Therapeutics, 1967
- The Modes of Decomposition of 1,3-Bis(2-chloroethyl)-1-nitrosourea and Related CompoundsJournal of Medicinal Chemistry, 1967